1 2 3	Low-cost generation of clinical-grade layperson-friendly pharmacogenetic passports using oligonucleotide arrays						
4	Authors and affiliations						
5	Pauline Lanting ^{1,2,3*} , Robert Warmerdam ^{1,3*} , Jelle Slager ¹ , Harm Brugge ¹ , Taichi						
6	Ochi ⁴ , Marloes Benjamins ¹ , Esteban Lopera-Maya ¹ , Soesma Jankipersadsing ¹ , Jody						
7	Gelde	rloos-Arends ¹ , Daphne Teuben ¹ , Dennis Hendriksen ^{1,6} , Bart Charbon ^{1,6} ,					
8	Lenna	rt Johansson ^{1,6} , Thijs Oude Munnink ² , Nienke de Boer-Veger ⁵ , Lifelines NEXT,					
9	LifeLin	nes Cohort Study, Bob Wilffert ^{2,4} [†] , Morris Swertz ^{1,6} , Daan Touw ² , Patrick					
10	Deeler	n ^{1,3} , Nine Knoers ¹ , Jackie Dekens ^{1,7#} , Lude Franke ^{1,3#}					
11 12 13 14 15	 * Contributed equally [†] Deceased # To whom correspondence should be addressed 						
16	1.	Department of Genetics, University Medical Center Groningen, University of					
17		Groningen, Groningen, The Netherlands					
18	2.	Department of Clinical Pharmacy and Pharmacology, University Medical					
19		Center Groningen, University of Groningen, Groningen, The Netherlands					
20	3.	Oncode Institute, Utrecht, The Netherlands					
21	4.	Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy,					
22		Epidemiology & Economics, University of Groningen, Groningen, The					
23		Netherlands					
24	5.	Service Apotheek Boterdiep, Groningen, The Netherlands					
25	6.	Genomics Coordination Center, Groningen, The Netherlands					
26	7.	Center for Development and Innovation, University Medical Center					
27		Groningen, University of Groningen, Groningen, The Netherlands					
28	NOTE: Th	nis preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.					

29 Abstract

30 Pharmacogenomic (PGx) information is essential for precision medicine, enabling 31 drug prescriptions to be personalized according to an individual's genetic 32 background. Almost all individuals will carry a genetic marker that affects their drug 33 response, so the ideal drug prescription for these individuals will differ from the 34 population-level guidelines. Currently, PGx information is often not available at first 35 prescription, reducing its effectiveness. Pharmacogenetic information is most often 36 obtained using special assays, making it expensive and time-consuming to generate. 37 We therefore hypothesized that we could also use genome-wide oligonucleotide 38 genotyping arrays to generate comprehensive PGx information (PGx passports). 39 thereby decreasing the cost and time required for PGx testing, and lowering the 40 barrier to generating PGx information prior to first prescription.

41

42 Taking advantage of existing genetic data generated in two biobanks, we developed 43 and validated Asterix, a low-cost clinical-grade PGx passport pipeline for 12 PGx 44 genes. In these biobanks we performed and clinically validated genetic variant 45 calling and statistical phasing and imputation. In addition, we developed and validated a novel CYP2D6 copy number variant calling tool, foregoing the need to 46 47 use separate PCR-based copy number detection. Ultimately, we returned 1227 PGx 48 passports to biobank participants via a layperson-friendly app, improving knowledge 49 of PGx among citizens. Our study demonstrates the feasibility of a low-cost clinical-50 grade PGx passport pipeline that could be readily implemented in clinical settings to 51 enhance personalized healthcare, ensuring that patients receive the most effective 52 and safe drug therapy based on their unique genetic makeup.

54 Keywords

55 Pharmacogenetics, pharmacogenomics, PGx profile, PGx passport, clinical56 pharmacogenomics

57

58 **1. Introduction**

59 There is now extensive knowledge available on pharmacogenes, and clinical 60 guidelines are available for personalized drug treatment using genetic data (1). 61 However, the application of pharmacogenetics (PGx) in clinical practice remains 62 limited (2) and is mostly done reactively to understand why patients reacted poorly to 63 prescribed drugs. However, a pre-emptive pharmacogenetic passport would allow 64 results to be stored in (electronic) medical files for future medical use (3), ensuring 65 that PGx data are available at first prescription, thereby enabling optimized treatment 66 and preventing adverse effects (4,5). Currently, the major impediments to such pre-67 emptive testing are cost and speed: PGx information is most commonly obtained 68 using dedicated assays that target a limited subset of haplotypes of a single gene. 69 This makes the generation of a complete, multi-gene profile time-consuming and 70 costly.

71

In theory, PGx data can also be obtained from genetic data that is routinely used in
both research and clinical genetics. Single nucleotide polymorphism (SNP)
microarrays in particular have proven essential for detection of Copy Number
Variations (CNVs) in clinical genetics and genome-wide association studies (GWAS)
in research (6,7). However, whether this data can be used to provide a clinical-grade
PGx passport to individuals is largely unknown, and there are a number of
challenges that need to be resolved before this data can be effectively used for PGx.

Firstly, SNP arrays do not consider every variant and do not capture on which haplotype specific information is located, requiring the use of genotype phasing and imputation. Secondly, *CYP2D6*, an important gene in pharmacogenomics (8) is highly polymorphic, and it is also affected by CNVs, making the genotyping of this gene non-trivial. To deliver on the promise of personalized medicine, we need to bridge these gaps in order to translate available genetic data to clinically relevant PGx data.

86

87 In parallel with the decreasing cost of genetic testing over the past decade, the 88 number of large-scale biobank initiatives has also increased. Jointly, these biobanks 89 have now generated genotype data for millions of individuals (9-12). This provides 90 an opportunity to repurpose readily available genetic data to develop and validate 91 the use of SNP array data for generating PGx passports. This would allow 92 researchers to return clinical-grade PGx results to biobank participants, thereby 93 decreasing the barriers to applying pre-emptive PGx testing and facilitating 94 personalized medicine in clinical settings.

95

Another problem is that the disclosure of PGx information so far has mainly been 96 97 limited to researchers, clinicians, and pharmacists. Yet sharing relevant PGx 98 information with citizens is important to improve knowledge and understanding of 99 PGx testing and its related health outcomes. Digital health technologies, including 100 mobile phone applications, have increased citizen engagement in the last 10 years 101 (13,14), and they allow patients to be engaged in the healthcare decision-making 102 process. Implementation of digital health technology in optimizing medication 103 adherence in patients with depression, respiratory diseases, and cancers has been

shown to improve patient outcomes. However, the use of digital health technologies
to provide PGx information to patients has been limited. However, with growing
populations throughout the world, governments are now actively stimulating the
development and use of such tools. For instance, the recent Integral Care
Agreement in the Netherlands highlights the importance of digitalization to promote
self-reliant digital healthcare (15).

110

111 In the northern Netherlands, the Lifelines Cohort Study, a multigenerational,

112 longitudinal, dynamic cohort and biobank, presents a unique opportunity to leverage

113 available genetic data to facilitate healthy aging (16). This biobank has been

114 genotyping its participants for multiple years, as has the separate Lifelines NEXT

prospective birth cohort biobank. In this study, we developed and clinically validated

1) an automated software tool for the interpretation of array-based genotype data to

117 generate reliable PGx profiles, 2) a layperson-friendly translation of Dutch

118 Pharmacogenetics Working Group (DPWG) guidelines, and 3) a digital infrastructure

to communicate these to biobank participants. By developing this tool, we aim to

120 improve the lives of patients and the general population, starting with the population

121 of the northern Netherlands and expanding to more individuals in the future.

122

123 2. Methods

124 2.1 Datasets and quality control

We used four different datasets to develop and validate the automated generation of
PGx passports, divided over two different versions of Illumina Genotyping arrays. We
used 38,030 samples from the UMCG Genetics Lifelines Initiative (UGLI) cohort of

the Lifelines prospective follow-up biobank (17) to develop and validate an

129 automated PGx passport pipeline using the Infinium Global Screening Array® 130 MultiEthnic Disease (GSA-MD) version 1.0 array. In parallel, we used three datasets 131 to develop the pipeline for the GSA-MD version 3.0 array: 2473 samples from our 132 Genome Diagnostics patient cohort (UMCG), 77 validation samples with known PGx 133 genotypes, and another 574 samples from the Lifelines NEXT cohort (18). 134 135 The samples of the Lifelines UGLI cohort were genotyped using GSA-MD version 136 1.0. We performed quality control on both samples and markers, including removal of 137 samples and variants with a low genotyping call rate (<97%), variants showing 138 deviation from Hardy-Weinberg equilibrium ($p < 1 \times 10^{-6}$), excess of Mendelian errors in families (>1% of the parent-offspring pairs), and samples with very high or low 139 140 heterozygosity (4 standard deviations (SD) above or below the mean for autosomes). 141 We further revised and removed samples that did not show consistent information 142 between reported sex and genotypes on the X chromosome, or between reported 143 familial information and observed identity-by-descent sharing with family members. 144 All other samples were genotyped using GSA-MD version 3.0 and were quality-145 controlled similarly to those in Lifelines UGLI. In total, 36,373 Lifelines UGLI 146 samples, 470 Lifelines NEXT samples, 2285 validation samples of the Genome 147 Diagnostics patient cohort, and 76 validation samples with known PGx genotypes 148 passed quality control.

149

150 2.2 Selecting individuals to receive pharmacogenetic results

Quality control measures in research settings are commonly less stringent than in
diagnostics. Since Lifelines UGLI samples were genotyped in a research setting, this
dataset could potentially contain sample swaps. Therefore, we used Idéfix (19) to

154 select a high-quality subset of 5,765 samples suitable for returning personalized 155 results. In short, Idéfix selects those samples for which the actual phenotypes 156 sufficiently match the predicted phenotypes based on genetic predispositions. These 157 genetic predispositions were determined by calculating polygenic scores (PGSs) per 158 phenotype. These calculations aggregate the effects of common risk-decreasing or -159 increasing alleles identified by GWAS. Here, we reran Idéfix using an updated list of 160 PGSs based on recent GWAS. Quality control, PGS calculation, and running Idéfix 161 were performed as described in Warmerdam et al. (19). Finally, we returned PGx 162 results to 996 active Lifelines participants who gave consent to receive their PGx 163 passport. For Lifelines NEXT, we were able to manually resolve sample swaps 164 based on family data and duplicated array runs. We returned PGx results to 231 165 mothers registered as active Lifelines NEXT participants who gave consent to 166 receive their PGx passport.

167

168 2.3 Variant calling

169 Variants were called in two separate stages. In general, we used the Opticall 170 software (20) to do genotype-calling on the majority of variants. However, Opticall is 171 not suitable for genotyping variants covering frequent CNVs. Since CYP2D6 is 172 affected by relatively frequent CNVs, it is not trivial to genotype variants within and 173 near this gene. At the same time, inclusion of CYP2D6 is essential to return a 174 comprehensive PGx passport because it metabolizes a large proportion of 175 medication. We therefore developed a novel algorithm for CNV-calling of the 176 CYP2D6 gene using the data obtained from a SNP array. In addition, this method 177 also performs genotype-calling of individual variants in the CYP2D6 gene.

179 2.3.1 CYP2D6

180 SNP arrays have been used extensively to study both SNPs and CNVs. Modern 181 SNP arrays genotype at hundreds of thousands of assays (probes designed to 182 genotype one particular variant) simultaneously by measuring the color and intensity 183 of light emitted when one of four labeled nucleotides hybridizes at the assays. In 184 addition to enabling study of which alleles are present in an individual through 185 comparison of the colors of the emitted light, it also allows study of CNVs by 186 combining the total signal intensity. We combined these two approaches in our 187 CYP2D6 genotyping methodology, as described below. 188 189 For genotyping CYP2D6, we first selected a number of independent, high-quality

190 variants from the quality-controlled genetic data (missingness < 0.01, minor allele 191 frequency (MAF) > 0.05, Hardy-Weinberg equilibrium p-value > 0.05, HLA excluded, minimum distance of 100kb between variants, $R^2 < 0.4$). Using these variants, our 192 193 method performs a principal component analysis of the intensities of the selected 194 variants (summed across the two alleles). As the first principal components (PCs) 195 likely tag batch effects, we chose to regress out the first 100 PCs from the genomic 196 region of interest – the CYP2D6 gene – using ordinary linear regression (OLS). Both 197 PC loadings and OLS regression parameters can be estimated in one dataset, and 198 later applied in another. The methodology for correcting SNP array intensities follows 199 the approach previously established by Lude Franke et al. (21).

200

After correction for batch effects, one variant is selected to assign naive CNV-calls (rs1135824 for GSA-MDv1, rs1423323203 for GSA-MDv3). Naive, preliminary CNV assignments are made by binning the total signal intensity of the selected variant so

204 that the proportions of CNV genotypes match the expected frequency of CNV-calls. 205 The expected frequencies ($^{*}5 = 0.0295$, Duplication = 0.0275) are obtained from 206 PharmGKB (https://www.pharmgkb.org/page/cyp2d6RefMaterials, European 207 population). Using the means and SDs of the signal intensities for each bin, a naive, 208 preliminary CNV call is assigned to every individual based on which CNV bin has the 209 highest likelihood at the signal intensity of the specific variant. If multiple GSA probes 210 are available for a variant, a majority voting ensemble classifier is used to obtain a 211 consensus of the various assays. Next, genotyping is performed using a manually 212 selected set of variants. These variants are selected based on whether the individual 213 signal intensities show clusters of genotypes in accordance with what can be 214 expected for a biallelic variant with possible deletions and duplications (i.e., at least 215 six visible intensity clusters rather than the three intensity clusters expected when 216 dealing with a biallelic variant outside a CNV).

217

218 For each variant and possible copy number, a nearest-neighbors classifier is used to 219 obtain a set of highly confident samples for every variant. Then, to perform 220 genotyping, the theta of every sample is calculated based on its intensities. For this, 221 the median of the intensities for the samples naively assigned to the group of 222 homozygous deletions is used as the origin. Thereafter, samples are binned into k 223 bins, where k corresponds to the number of genotypes that can be expected for a 224 biallelic variant at each copy number. Bins are assigned genotypes so that they best 225 match Hardy-Weinberg principles. Per variant, naive genotype clusters are then 226 iteratively improved in a gaussian mixture model algorithm adapted from scikit-learn 227 (22). The maximization step in the gaussian mixture model algorithm was changed to 228 also weight genotypes according to Hardy-Weinberg principles, which were

expanded to also take deletions and duplications into account. Per variant, this
procedure is performed while accounting for the intensity measures of all assays
tagging that specific variant.

232

233 For each combination of a variant, sample and copy number, a total probability is 234 calculated by summing the probabilities across the genotypes corresponding to that 235 copy number. Subsequently, the most likely copy number is assigned to each 236 variant-sample combination by selecting the copy number with the largest total 237 probability among the possible copy numbers. The CNV status of CYP2D6 as a 238 whole is determined by summing the probabilities of variants over all possible copy 239 numbers, and rescaling these to sum to one. Genotype probabilities are then 240 calculated by rescaling the possible genotype probabilities in the assigned copy 241 number status to one.

242

243 Genotypes of samples with 1 or 2 CYP2D6 copies (across both the maternal and 244 paternal chromosome) are written so that genotypes of samples with single-gene 245 deletions are homozygous for the reanalyzed variants. Genotypes for variants of 246 samples that are homozygous for whole-gene deletions do not exist. In human 247 genetic datasets, the representation of genotypes for variants of samples with a 248 CYP2D6 duplication is not trivial, making the imputation and phasing non-trivial. 249 Therefore, these samples are excluded. CYP2D6 variants in chromosome 22 250 genotyped using Opticall are replaced with the newly genotyped CYP2D6 variants. 251 This is subsequently used in the phasing and imputation pipeline. The CYP2D6 252 CNV-calling algorithm is included as the first part of the Asterix software that we 253 developed to generate PGx profiles.

254 2.4 Phasing and imputation pipeline

255 Before phasing and imputation, PLINK files are lifted from Human genome build 37 256 to build 38 and alleles of insertions and deletions are recoded to match the notation 257 in the reference dataset. Then, variants for which the strands do not match the 258 reference panel are removed, and variants with >5% missingness or a Hardy-Weinberg p-value $< 1 \times 10^{-6}$ are removed. Phasing and imputation are implemented 259 260 using Eagle v2.4.1 (23) and Minimac4 (24)(version 1.0.2). The reference dataset for 261 phasing and imputation is derived from the 1000 Genomes project 30x coverage 262 whole genome sequencing dataset (25). Finally, we replaced the imputed genotypes 263 with the original genotypes for the variants that were used as input in the imputation. 264 265 2.5 Crucial backbone 266 A minimum set of variants that should be included in our genotyping panel was 267 determined per gene (see Table S1). We used available 'tier 1' recommendations for 268 CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, and VKORC1 (26-29). For the

269 other genes in our PGx passport, we assessed the variants/alleles that were

270 mentioned in DPWG background information and those that are included in our

validation dataset. We included a variant in the crucial backbone when: 1) the variant

results in an allele known to alter the drug response phenotype, and 2) the MAF in

the (North-Western) European population is > 0.001.

274

275 2.6 Validation

We validated GSA-MD versions 1 and 3 and *Asterix* following the clinical genome
diagnostic standards in our center. The validation parameters and corresponding
acceptance criteria are shown in Table 1.

- 279 Table 1: Validation parameters and acceptance criteria for the clinical validation of the Infinium Global Screening
- Array MultiEthnic Disease versions 1 and 3, and the software tool Asterix. ‡For all variants available in both
- 281 gnomAD-NFE and GoNL datasets, the distribution of mutant allele frequency differences between those two
- 282 datasets was recorded. Z represents the standard deviation of that distribution. Variants that deviated more than
- 283 3*Z from the gnomAD-NFE mutant allele frequency failed validation.

Торіс	Validation parameter	Acceptance criterium	
Quality of the array data	Call rate	³ 0.97	
Phasing and	Concordance with trio-data	³ 0.97	
imputation quality	R ²	³ 0.97	
Result interpretation	Absolute number of mutant alleles detected	³ 5	
	Mutant allele frequency	<3*Z [‡]	
	Concordance with known genotypes	100%	

284

285 We created a benchmark set of haplotypes using data of 621 (GSA-MD v1) and 135 286 (GSA-MD v3) parent-offspring trios to validate phasing performance. Using 287 SHAPEIT5 (30) we then compared the results of our statistical phasing with the 288 benchmark haplotypes and computed the switch error rates (SER) of all genetic 289 variants that were directly typed. The call rate and imputation quality are validated 290 based on the output of our quality control procedures. Variants were removed if: 1) 291 they were not directly genotyped nor imputed, 2) they were not in the crucial backbone and had a low imputation probability ($R^2 < 0.97$), 3) the mutant allele was 292 293 observed < 5 times in the full dataset, 4) the mutant allele frequency deviated more 294 than 3*Z from the gnomAD-non-Finnish Europeans (NFE) mutant allele frequency (Z 295 represents the SD of differences in mutant allele frequency between the GoNL and 296 gnomAD-NFE datasets), 5) the phasing SER was > 0%, or 6) the concordance with 297 known genotypes of validation samples was < 100%.

When a variant was in the crucial backbone, but the imputation probability was low, we used haploid-level dosage (HDS) to assess the variant call confidence level in an individual sample.

302

303 In addition to variant calling, we also validated our CNV-calling algorithm. To that

304 end, we selected samples with a confidence score of > 0.97 (1x zero copies, 14x one

305 copy, and 16x two copies) and samples with a confidence score of with a CNV-

calling confidence score of > 0.9, and < 0.97 (4x one copy, 3x two copies and 5x

307 three copies). DNA of these samples was analyzed with a dedicated TaqMan real-

308 time PCR assay specifically targeting exon 9 of the CYP2D6 gene (Certe,

309 Groningen, the Netherlands). It is worth noting that this assay cannot detect gene

310 duplication or hybrid alleles. However, as we report *CYP2D6* to be not available

311 when >2 copies of *CYP2D6* are detected, these calls do not currently require

312 validation.

313

Finally, we confirmed that the software we developed correctly translated 1) the detected mutations to the corresponding star alleles and, subsequently, 2) the combination of haplotypes to the corresponding contraindication (CI) and/or predicted phenotype. This is described in more detail in section 2.9.3 and in the Supplementary Information.

319

320 2.7 Pruning of allele definition tables

We used gene-specific allele definition tables to assign star alleles. Available tables
were downloaded from PharmVar (v5.2.14 for GSA-MD version 3; v6.0.5 for GSAMD version 1) for *CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5* and

- 324 *NUDT15* and from PharmGKB for *ABCG2* and *TPMT*
- 325 (https://www.pharmgkb.org/page/pgxGeneRef). Custom tables were constructed for
- 326 MTHFR, SLCO1B1 and VKORC1. We curated all allele definition tables for the GSA-
- 327 MD versions 1 and 3 separately and removed all variants that did not pass
- 328 acceptance criteria (Tables S2a-b). We then pruned each table to prevent
- ambiguous calls caused by haplotypes that we cannot distinguish based on the
- 330 variants included in our pipeline. The resulting allele definition tables are shown in
- 331 Tables S3a-x.
- 332

333 2.8 Translation to pharmacogenetic contraindication

To translate the diplotype to the PGx CI used in medication surveillance, we

designed custom translation tables (see Tables S4a-I). Allele function of individual

336 star alleles and their translation into predicted phenotype and PGx CI are based on

337 PharmVar, PharmGKB, and/or DPWG background information. All possible

diplotypes based on the pruned allele definition tables are included in the translation

tables. We made sure the PGx CIs correspond to those used in the DPWG

340 recommendations.

341

342 2.9 Generating PGx profiles

343 We developed the *Asterix* tool to produce PGx profiles from genotyping data from

the GSA-MD versions 1 and 3. *Asterix* is composed of four main tasks: 1)

345 determining the *CYP2D6* copy number status, 2) determining star alleles, 3)

translating these to predicted phenotypes and PGx CIs, and 4) constructing a

347 logging file.

349 2.9.1 Determining star alleles, predicted phenotypes, and PGx CIs

After correction of the *CYP2D6* genotypes based on the CNV status, star alleles for all included genes are assigned using the gene-specific allele definition tables. Subsequently, predicted phenotypes and PGx CIs are determined with the custom translation tables. When determining star alleles present for *CYP2D6*, *Asterix* takes into account whether whole-gene deletions (*CYP2D6*5*) were detected in CNVcalling.

356

357 2.9.2 Constructing a logging file

To be able to check *Asterix* output, an extensive logging file is constructed that
contains information for several checkpoints in our pipeline. Parameters that are

360 logged include the estimated phased haploid-level dosage (HDS) when < 0.97 (only

for imputed genotypes), missing variants, and haplotypes that were not described in
 translation tables. Identical haplotypes are merged together to simplify the validation
 process.

364

365 2.9.3 Approval and release of the PGx profiles

The PGx profiles generated are to be released by a registered pharmacist. To maximize process efficiency, the approval and release of the PGx profiles is performed on the level of unique combinations of detected mutations and unreliable calls. When a sample contains only previously approved haplotypes, it is automatically released. Each decision is logged to maintain an audit trail. The procedure for approving and releasing the profiles is described in more detail in the Supplementary Information.

374 2.10 Building layperson-friendly PGx passports

The output of *Asterix* is a PGx profile that is suitable for application in clinical practice by healthcare practitioners. However, (future) patients should not be expected to understand the meaning or implications of such a profile. We therefore developed a layperson-friendly digital PGx passport to fulfill the informational needs of (future) patients.

380

381 2.10.1 Developing layperson-friendly communication materials

382 We aimed to develop communication materials that explain the impact of drug–gene

interactions (DGIs) that are understandable for 90% of the study population. We

384 developed layperson-friendly texts based on the DPWG guidelines for healthcare

385 practitioners (see Table S5), written at Common European Framework of Reference

386 Common Reference Level B2 (31). One important difference that we had to address

is that the DPWG guidelines do not contain an explanation for normal metabolizers

388 because standard-of-care applies for these patients. However, texts for the (future)

389 patient do need to cover this topic because it is valuable to explain that standard-of-

390 care applies. The texts are constructed using three building blocks (Figure 1).

Block 1: Predicted influence of your DNA	Predicted influence of your DNA
Block 1: Predicted influence of your DNA.	Predicted influence of your DNA or pharmacist can tell you more about the appropriate dose.

392

393 Figure 1: Building blocks used to construct layperson-friendly texts to explain Drug–Gene interactions (left) and

394 the corresponding text for CYP2D6 PM-amitriptyline (translated from Dutch, right).

396 2.10.2 Digital infrastructure

397 We created a DGI table that contains all the CIs produced by Asterix, a list of known 398 DGIs currently in the DPWG guidelines, and the layperson-friendly texts associated 399 to each combination of these. The relevant texts for each participant are selected 400 based on their PGx profile and known DGIs. For example, the text explaining the 401 consequences for amitriptyline in Figure 1 will be selected for the individuals who are 402 listed as CYP2D6 PM in their PGx profile. The PGx profile and corresponding texts 403 are subsequently unlocked through an Application Programming Interface (API) 404 following the Health Level Seven Fast Healthcare Interoperability Resources (HL7-405 FHIR) format. Participants can view their PGx passport in the mobile application 406 (app) Gen en Geneesmiddel, which we developed with Synappz Digital Healthcare 407 and which is available for iOS and Android (see Figure 5). 408

409 2.10.3 Additional features

Upon installing the app, the user is shown a series of information screens that
explain PGx and the content and use of the app. This information can be reviewed
within the app after completion of this initial onboarding process. Furthermore,
frequently asked questions (FAQ) are included in the app to address several
anticipated questions. The FAQ-section is supplemented by new questions from
users and associated answers.

416

The layperson-friendly texts displayed in the mobile application are accompanied by articles that describe the PGx CI that interacts with the drug being viewed (see Table S5). When multiple PGx CIs are relevant for the drug being viewed, all the relevant articles are shown. The articles provide interested participants with more detailed

421 information and facilitate communication between (future) patients and healthcare422 practitioners.

423

424 Finally, a technical report aimed at healthcare practitioners can be downloaded from

425 the app. This report contains the PGx profile and accompanying information,

including contact information for a helpdesk and instructions on how to interpret and

427 process the results.

428

429 **3. Results**

430 3.1. Pharmacogenomic profiles and passports

431 To validate the use of a layperson-friendly, clinical-grade PGx passport using

432 oligonucleotide arrays, we have developed a tool (*Asterix*) to produce PGx profiles

433 from genotyping data from the GSA-MD versions 1 and 3. As described in Figure 2a,

434 our tool works by determining the *CYP2D6* copy number, phasing and imputing

435 genetic variants, determining the star alleles of the samples provided, and translating

436 diplotypes to PGx CIs. Instructions on the installation and use of Asterix are

437 described on the GitHub repository (<u>https://github.com/molgenis/asterix</u>).

438

439 3.2. Validation

440 A total of 34 variants, in 12 genes, were included in the crucial backbone of the PGx

441 pipeline, and subsequently underwent validation (Table 2). For CYP2B6 we initially


442 also included rs3211371 (*5). However, since the DPWG withdrew CI definitions

443 differentiating *CYP2B6*5* from **1*, we removed this SNP from the crucial backbone.

444 Three variants in *CYP2C9* (rs28371686 (*5), rs9332131 (*6) and rs7900194 (*8))

445 were initially included in the crucial backbone based on their multiethnic allele

- 446 frequency (26). However, since each of these variants had a MAF < 0.001 in the
- 447 NFE population, we subsequently excluded them from the crucial backbone for GSA-
- 448 MD v1. It is important to note that the Lifelines population is known to be reflective of



449

450 Figure 2: Overview of the work in this paper. (a) Schematic of the pharmacogenetic (PGx) pipeline developed to 451 generate PGx profiles. Data collection involves obtaining DNA samples from participants and genotyping using 452 an oligonucleotide array. We ascertain CYP2D6 copy numbers (CN) using a custom CNV calling approach. This 453 method estimates CN status at multiple points within the CYP2D6 gene and integrates these estimates to 454 determine the overall gene copy number status. Twelve genes contribute to the generation of PGx profiles. The 455 combined effects of these genes are aggregated into medication-level recommendations, which are 456 communicated to participants via a layperson-friendly app. (b) Broad overview of the methodology used for

- 457 validating the PGx pipeline. (c) Overview of the datasets used for development and validation of the PGx
- 458 passport (Development datasets), and those for which we also returned PGx-profiles (Repurposed datasets).
- 459
- the NFE population. For the same reason, we excluded rs41303343 (*CYP3A5**7).
- 461 For TPMT variant rs1800462 (*3A/*3B), no mutant alleles were detected on GSA-MD
- 462 v3. As we could not ensure the associated GSA probe was functional, *TPMT* was
- 463 excluded from PGx profiles generated with GSA-MD v3. All other variants in the
- 464 crucial backbone passed validation criteria. In case of an imputation score (R²) <
- 465 0.97, imputation quality was judged from sample-specific HDS. When the HDS <
- 466 0.97, a registered pharmacist decided during approval and release whether a result
- 467 could be released for the associated gene.
- 468
- 469 Table 2: Validation results of crucial backbone variants.
- 470 ^ars28371686, rs9332131, and rs7900194 were left out of crucial backbone for GSA-MD v1, based on known
- 471 ethnic composition of Lifelines
- 472 ^brs41303343 was left out of the crucial backbone for both GSA-MD v1 and GSA-MD v3, based on known ethnic
- 473 composition of Lifelines
- 474 ^cReference allele frequency in non-Finnish Europeans (NFE)

			GSA-MD v1		GSA-MD v3		v3
Gene	rsID	Alt. allele frequency ^c	method	R ²	method	R ²	failed validation
ABCG2	rs2231142	0.1092	direct		direct		
CYP2B6	rs3745274	0.2372	direct		direct		
	rs4244285	0.1480	direct		imputation	0.99	
CYP2C19	rs4986893	0.0002	direct		direct		
	rs12248560	0.2200	direct		direct		
	rs1799853	0.1266	imputation	0.99	imputation	1.00	
	rs1057910	0.0662	direct		direct		
CYP2C9	rs28371686	0.0000	(imputation) ^a	(0.02)	direct		
	rs9332131	0.0001	(imputation) ^a	(0.00)	direct		
	rs7900194	0.0005	(imputation) ^a	(0.01)	imputation	0.90	

			1				
	rs28371685	0.0029	direct		direct		
	rs1135840	0.5588	imputation	0.87	imputation	0.93	
	rs16947	0.3347	imputation	0.89	imputation	0.96	
	rs35742686	0.0170	imputation	0.79	imputation	0.82	
	rs3892097	0.1986	imputation	0.91	imputation	0.92	
	rs5030655	0.0117	imputation	0.61	imputation	0.27	
CYP2D6	rs5030656	0.0285	imputation	0.67	imputation	0.70	
011 200	rs1065852	0.2225	imputation	0.91	imputation	0.95	
	rs28371706	0.0011	direct		imputation	0.86	
	rs61736512	0.0006	imputation	0.04	imputation	0.97	
	rs59421388	0.0006	imputation	0.04	imputation	0.97	
	rs1058164	0.5525	imputation	0.86	imputation	0.93	
	rs28371725	0.0955	imputation	0.84	direct		
CYP3A4	rs35599367	0.0492	direct		direct		
	rs776746	0.9311	direct		direct		
CYP3A5	rs10264272	0.0009	direct		direct		
	rs41303343	0.0004	(imputation) ^b	(0.96)	n/a⁵		
MTHFR	rs1801133	0.3373	direct		direct		
NUDT15	rs116855232	0.0029	direct		direct		
SLCO1B1	rs4149056	0.1587	direct		direct		
						<5	
ТРМТ	rs1800462	0.0024	imputation	0.46	direct	mutants detected	
	rs1800460	0.0382	imputation	0.96	direct		
	rs1142345	0.0423	imputation	1.00	direct		
VKORC1	rs9923231	0.3779	direct		direct		

475

476 We considered 731 and 703 variants outside the crucial backbone for inclusion in the 477 translation tables of GSA-MD v1 (PharmVar tables v6.0.5) and GSA-MD v3 478 (PharmVar tables v5.2.14), respectively. Results of the validation process are 479 summarized in Figure 3 and are fully available in Tables S2a-b. Many variants were 480 removed due to unavailability on the genotyping arrays and in the imputation panel. 481 Beyond that, poor imputation score and/or low allele frequency were the leading 482 reasons for exclusion. Phasing quality was verified by comparison to phasing results 483 using parent-offspring trios. Poorly phased variants were retained when they were


484 the only variant of interest in that gene, rendering phasing irrelevant. Importantly, 37

485 variants were typed in 76 validation samples, using a traditional DNA amplification

486 genotyping method (Leiden University Medical Center). For all 37 variants, the

- 487 genotypes derived from GSA-MD v3 (19 directly typed, 18 imputed) were a 100%
- 488 match to the traditional assays.


489




490

Figure 3: Validation status of variants from the PharmVar translation tables outside the crucial backbone. The UpSet plot displays the frequency of variants that either meet or fail to meet the validation criteria. Columns with a single marked circle represent the frequency of variants failing exclusively that criterion, while columns with multiple marked circles indicate variants that failed multiple corresponding criteria.

495 Within Asterix, we embedded a custom CYP2D6 copy number (CN) calling 496 algorithm. To validate the Asterix-derived CYP2D6 CN calls, a total of 43 samples 497 were selected, representing a CN probability of at least 0.9 and each of the four 498 possible CN calls (zero copies, one copy, two copies, and three copies). The CN 499 status of the aforementioned samples was determined using a dedicated TagMan 500 assay targeting exon 9. To compare the results, we initially evaluated whether the 501 overall CN calls with a moderate probability of over 0.9 matched the calls reported by 502 the TaqMan assay (Figure 4a). Of the 43 samples, Asterix identified three as having





513 a CYP2D6 duplication (three copies), whereas the TagMan assay reported these 514 samples as homozygous reference (two copies). In one instance, Asterix reported a 515 heterozygous deletion (one copy) while the TagMan assay returned a homozygous 516 reference call. However, for these four samples, Asterix consistently reports a 517 homozygous reference call at exon 9, which is consistent with the call reported by 518 the TagMan assay. For the majority of the other variants, Asterix reports calls 519 matching that of the overall aggregated estimate (Figure 4b). This suggests that 520 these samples are likely to possess a hybrid allele or tandem arrangement, resulting 521 in a distinct CN call at exon 9. It is worth noting that the TagMan assay is not 522 capable of differentiating between regular copy numbers and hybrid alleles. At a 523 probability of at least 0.97, all 31 samples exhibit matching CN calls. 524 525 Based on the validated variants, final translation tables were created to first translate 526 variants to haplotypes (Tables S3a-x) and then to translate diplotypes to CI (Tables

527 S4a-I). These tables were then used as input for *Asterix* to create preliminary PGx

528 profiles for 996 Lifelines participants and 470 Lifelines NEXT participants. Approval

529 (or adjustment) and release by a registered pharmacist resulted in the final PGx

530 profiles. Haplotype frequencies were compared to reference frequencies in a

531 European population (source: Clinical Pharmacogenetics Implementation

532 Consortium (CPIC)) or NFE (source: DPWG/gnomAD) (Figure 4 and Tables S6a-b).

533

534 Finally, the technical PGx profiles were shared with the biobank participants in the 535 smartphone application *Gen en Geneesmiddel* (Figure 5). The app links the 536 technical information in the PGx profile with associated explanatory texts, yielding a 537 layperson-friendly PGx passport. Rather than using genes as the basic unit of

538 information, the app categorizes drugs into five categories (Figure 5a): poor 539 metabolism ('very slow'), intermediate metabolism ('slow'), normal metabolism 540 ('average'), ultrarapid metabolism ('very fast'), and non-metabolic drug-gene 541 interactions ('other processes'). By selecting one of the categories, users can see a 542 list of all the medications in that category, based on their pharmacogenetic profile 543 (Figure 5b). More information can be found on specific medication (Figure 5c), i.e., 544 what is it used for and how is it affected by the user's PGx profile. Interested users 545 can get more information on the associated CIs by proceeding to a linked article. 546 Finally, the technical information (PGx profile) can be downloaded and/or shared 547 directly from the app (Figure 5d). 548 549 Based on the PGx profiles we generated using Asterix, 92% and 90% of the Lifelines 550 and Lifelines NEXT populations, respectively, carried at least one actionable PGx CI 551 (Tables S6a-b list frequencies of PGx haplotypes and CIs). We have returned these 552 profiles to the biobank participants through the Gen en Geneesmiddel app, enabling them to get optimized (future) drug prescriptions with the help of their physician and 553 554 pharmacist.

а	b	с	d
Find my medicine	← Very slow processing	← Very slow processing	Technical report
Very slow processing	This is the list of drugs that, according to your genes, are processed much more slowly than average	When prescribing medication, your (family) doctor or pharmacist will also look at factors such as age, sex, and other medications you are taking. Based on that complete picture, they will see whether brexpiprazole and the standard dosage are the best choice for you. It is possible that your (family doctor or pharmacist	
25 Medicines that you process much more slowly than average	Aripiprazole >	has already determined that your medication and dosage are suitable for you. Warning: never change the dosage of your drugs or stop using your drugs	
()	Atomoxetin >	without consulting your (family) doctor or pharmacist. This is what the medicine does:	Create your technical report here to
Slow processing >	Brexpiprazol >	Brexpiprazole is an antipsychotic drug. It inhibits hallucinations and delusions. Brexpiprazole is	Share Create a PDF of the technical report of your
Medicines that you process slightly more slowly than average	Carvedilol >	prescribed for psychoses and schizophrenia. For more information about brexpiprazole, click here. Source: Guideline on pharmacogenetics of the	pharmacogenetic passport here to share. For example with your (family) dcotor and/or pharmacist
<u></u>	Clozapine >	professional organization for pharmacists (KNMP), September 2022.	
Average processing	Codeine >		Create technical report
Medicines that you process at average rate	Doxepin >	More information:	
× 1 000	Eliglustat >	CYP2D6 PM >	

556

557 Figure 5: Overview of the 'Gen en Geneesmiddel' app (translated from Dutch). a) Main menu, where five 558 categories can be selected: 'poor', 'intermediate', 'normal' and 'ultrarapid' metabolism and 'other processes'. b) A 559 personalized list of medication in the 'poor metabolism' category. c) Explanation of the predicted metabolism of 560 brexpiprazole. d) The pharmacogenetic profile can be saved or shared from the app.

561

562 4. Discussion

563 In this study, we use oligonucleotide genotyping arrays to develop a low-cost PGx 564 passport that repurposes existing genotype data from the Lifelines and Lifelines 565 NEXT cohorts for clinical use. We clinically validated the genotyping method by 566 aligning validation parameters and corresponding acceptance criteria to the local 567 clinical diagnostic center and by comparing genotyping results with results from 568 classical PCR-based assays. Using parent-offspring trios, we could also verify the 569 accuracy of haplotype phasing, information that is unavailable when using PCR-570 based PGx assays. We showed that we could confidently include most of the 571 recommended 'tier 1' PGx variants for the genes included in our study (26–29), with 572 only a few exceptions. TPMT was excluded for the GSA-MDv3 oligonucleotide array 573 because variant rs1800462 did not meet validation criteria. In addition, three 574 CYP2C9 variants classified as tier 1 (mutant allele frequency > 0.001) were excluded from the crucial backbone on the grounds of their much lower allele frequencies in 575

576 the European population. To apply our pipeline in a broader context, these variants 577 would need to be validated in a population with higher MAFs.

578

579 Furthermore, to address previously identified barriers to use of PGx passports by

580 laypeople, we implemented communication of relevant PGx information through a

newly developed smartphone application. As the uptake of the PGx passport

582 increases, support will be provided for healthcare professionals to properly apply

583 PGx in their daily practice.

584

585 4.1 Producing PGx profiles

586 As the generation of clinically valid PGx profiles from array-based genotype data is 587 the cornerstone of this study, we discuss this first. We did not include DPYD, FV, 588 HLA-A, HLA-B, CYP1A2, and COMT in the PGx passport because: 1) DPYD 589 genotyping is already pre-emptively performed in combination with phenotyping in 590 routine care, 2) the DPWG quidelines for mutations in FV were retracted, 3) there is 591 no allele definition table for determining HLA alleles, so we could not use the same 592 pipeline for this region, and 4) CYP1A2 and COMT are part of DPWG guidelines but 593 currently do not contain DGIs.

594

595 An important limitation in our passport production is that we could not provide a 596 complete passport for every individual. The reason is twofold: First, we used 597 imputation quality (\mathbb{R}^2) to select imputed variants of sufficient quality. If a variant with 598 insufficient imputation quality ($\mathbb{R}^2 < 0.97$) was in the crucial backbone, the variant 599 was not removed from the translation tables, as that would lead to the complete 600 exclusion of the corresponding gene for all individuals. Instead, we use haploid

601 dosage scores to select a subset of individuals with imputed genotypes of sufficient 602 quality. We could thereby still report results for a subset of individuals. When 603 applying our method in a diagnostic setting, genotypes should be determined by a 604 back-up analysis if no reliable result can be extracted from the array data. Second, 605 our CYP2D6 CNV-calling is currently aimed at detecting whole gene deletions and 606 duplications, ignoring potential hybrid alleles. While this is an important limitation, our 607 method is already able to determine CNV-status on the level of single variants as 608 opposed to the full locus. So far, we have used this to our advantage to ensure that 609 CNV-status across the entire gene is consistent, before a whole gene deletions or 610 duplications is called. However, this could also be used to call hybrid alleles, allowing 611 us to assess structural variation on a much higher resolution than currently achieved 612 in diagnostic settings, without the need for more expensive sequencing technologies. 613 Within the scope of this study however, we were unable to develop this.

614

We confirm that actionable PGx variants are present in >90% of the general population (Table S7), comparable to the percentages reported in literature. In this implementation study, we were unable to evaluate the impact of these actionable variants on drug efficacy and adverse effects, due to the scale of our study and the absence of high-quality prescription records for our study populations. In the future, we aim to further investigate this by linking prescription data from an external database through the PharmLines initiative (28).

622

623 4.2 Layperson-friendly communication of PGx passports

624 Engaging patients with PGx testing is not limited to increasing their understanding of

625 genetic information, it is also meant to enable their participation in prescription

decisions. Patients who are well-informed about the implications for their prescription
management are better equipped to collaborate with their healthcare providers in
developing personalized treatment plans that align with their needs and preferences
(32). Furthermore, this engagement builds a sense of empowerment and ownership
over one's health, which has been shown to improve adherence to treatment
regimens and to lead to better health outcomes (33).

632

The PGx passport, as a digital health tool, facilitates patient engagement by
providing a platform to exchange PGx information and medication management to
enhance patient understanding. By providing layperson-friendly communication
within the PGx passport, it may in the future be used to support patient education
initiatives to broaden the understanding and implementation of pharmacogenomics
across the Netherlands.

639

We aimed to develop communication materials that are understandable for 80% of the general population. Since the Lifelines and Lifelines NEXT cohorts are more highly educated than the general population, we speculate that the material should be understandable for around 90% of the study population. In an ongoing implementation study, we will evaluate the level of comprehension among participants, so that texts can be better adapted to citizens' needs.

646

Several practical decisions were made in the development of the smartphone
application. For example, *CYP3A5* non-expressers (*3/*3) were placed in the app
category that represents normal metabolism, while both hetero- and homozygous
expressers are placed in the ultrarapid metabolism category. In the Netherlands,

651 *CYP3A5* non-expressers are most prevalent, so the standard of care applies for 652 people with this metabolizer status.

653

654 4.3 Future perspectives

655 The completion of the PGx passport and smartphone application represents another

656 step forward on the road toward true personalized medicine. By demonstrating to

657 healthcare professionals how incorporating PGx into daily practice works to

658 streamline prescribing practices through the added value of reduced adverse effects,

the PGx passport aims to lower the barrier to making key prescription decisions.

660

661 Although clinical implementation of PGx has picked up pace in the past years, it has 662 not yet been integrated into routine care. One of the main barriers here is likely to be 663 the lack of strong evidence that its application effectively improves healthcare and 664 reduces healthcare costs, which are both prerequisites for reimbursement (34). 665 Other important potential barriers are the complexities associated with integrating 666 genetic data into electronic health records and the need to ensure that healthcare 667 professionals have the requisite expertise and resources to comprehend and utilize 668 PGx insights (35,36). Previous research at our center has shown that, although 669 these barriers exist, they can be overcome (2).

670

In this study, we have demonstrated that PGx passports can be generated much more cheaply than the currently prevailing methodologies. However, the efficacy and cost-effectiveness of pre-emptive PGx testing still needs to be more thoroughly proven, and this will require the inclusion of large numbers of participants from the general population. Only then will the numbers of drug prescriptions dispensed

676 based on the information in a PGx passport be sufficient to perform quantitative 677 analysis of adverse effects and/or treatment effectiveness. As the PGx passport is 678 currently limited to the Netherlands, the findings on cost-effectiveness would only be 679 applicable to the Netherlands. However, with the push to harmonize the European 680 Health Data Space, demonstrating cost-effectiveness in the Netherlands will enrich 681 the changing digital health space. Lastly, as the initial data was derived from the 682 Lifelines biobank, incorporating Asterix into future investigations in Lifelines would 683 enable more in-depth research into the interplay between genetic variation, 684 environment, population health, and pharmacotherapy.

685

686 4.4 Concluding remarks

687 This study provides a method to produce low-cost, clinically validated PGx profiles 688 for use by healthcare professionals from genotype array data. As more and more 689 individuals are genotyped, both in academic and healthcare settings, translating 690 available genetic data towards clinical decision-making will be essential for 691 personalized care. Furthermore, we have developed a smartphone application to 692 ensure that the results from our pipeline, Asterix, reach those whose health may be 693 impacted. To break down barriers to patient engagement, the application provides a 694 novel approach to understandably communicate PGx results to laypeople. The 695 reception of this information by users will be reported in an upcoming publication. 696 Future steps include the evaluation of the costs and effectiveness of the pre-emptive 697 PGx passport in the general population and further research into the interplay 698 between genetic variation and population health and drug response phenotypes.

699 References

- 1. Abdullah-Koolmees H, Keulen AM, Nijenhuis M, Deneer VHM.
- 701 Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC,
- 702 CPNDS, and RNPGx Guidelines. Front Pharmacol. 2021 Jan 25;11:595219.
- 2. Lanting P, Drenth E, Boven L, Hoek A, Hijlkema A, Poot E, et al. Practical
- 704 Barriers and Facilitators Experienced by Patients, Pharmacists and Physicians to
- the Implementation of Pharmacogenomic Screening in Dutch Outpatient Hospital
- Care-An Explorative Pilot Study. J Pers Med. 2020 Dec 21;10(4):293.
- 3. Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, et al. Multisite

investigation of strategies for the clinical implementation of pre-emptive

pharmacogenetic testing. Genet Med. 2021 Dec;23(12):2335–41.

4. Swen JJ, Wouden CH van der, Manson LE, Abdullah-Koolmees H, Blagec K,

711 Blagus T, et al. A 12-gene pharmacogenetic panel to prevent adverse drug

reactions: an open-label, multicentre, controlled, cluster-randomised crossover

713 implementation study. The Lancet. 2023 Feb 4;401(10374):347–56.

5. Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, et

al. Clinical implementation of preemptive pharmacogenomics in psychiatry.

eBioMedicine [Internet]. 2024 Mar 1 [cited 2024 Aug 27];101. Available from:

717 https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00044-

718 6/fulltext

6. Mason-Suares H, Kim W, Grimmett L, Williams ES, Horner VL, Kunig D, et al.

720 Density matters: comparison of array platforms for detection of copy-number

variation and copy-neutral abnormalities. Genetics in Medicine. 2013 Sep1;15(9):706–12.

- 723 7. Momtaz R, Ghanem N m., El-Makky N m., Ismail M a. Integrated analysis of
 724 SNP, CNV and gene expression data in genetic association studies. Clinical
 725 Genetics. 2018;93(3):557–66.
- 726 8. Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A Review of
 727 the Important Role of CYP2D6 in Pharmacogenomics. Genes. 2020
- 728 Nov;11(11):1295.
- 9. Leitsalu L, Haller T, Esko T, Tammesoo ML, Alavere H, Snieder H, et al. Cohort
- 730 Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu.

731 International Journal of Epidemiology. 2015 Aug 1;44(4):1137–47.

- 10. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank:
- An Open Access Resource for Identifying the Causes of a Wide Range of

734 Complex Diseases of Middle and Old Age. PLOS Medicine. 2015

- 735 mrt;12(3):e1001779.
- 11. Littlejohns TJ, Sudlow C, Allen NE, Collins R. UK Biobank: opportunities for
 cardiovascular research. European Heart Journal. 2019 Apr 7;40(14):1158–66.
- 12. Minegishi N, Nishijima I, Nobukuni T, Kudo H, Ishida N, Terakawa T, et al.
- 739Biobank Establishment and Sample Management in the Tohoku Medical
- 740 Megabank Project. The Tohoku Journal of Experimental Medicine.
- 741 2019;248(1):45–55.

- 742 13. Mahajan S, Lu Y, Spatz ES, Nasir K, Krumholz HM. Trends and Predictors of
- 743 Use of Digital Health Technology in the United States. Am J Med. 2021
- 744 Jan;134(1):129–34.
- 14. Shen N, Jankowicz D, Strudwick G. Patient and Family Engagement Approaches
- for Digital Health Initiatives: Protocol for a Case Study. JMIR Research Protocols.
- 747 2021 Jul 21;10(7):e24274.
- 748 15. Integraal Zorg Akkoord. 2022 Sep;
- 16. Sijtsma A, Rienks J, Harst P, Navis G, Rosmalen JGM, Dotinga A. Cohort Profile
- 750 Update: Lifelines, a three-generation cohort study and biobank. Int J Epidemiol.
- 751 2022 Oct 13;51(5):e295–302.
- 752 17. Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM, et al. Cohort
- 753 Profile: LifeLines, a three-generation cohort study and biobank. International
- 754 Journal of Epidemiology. 2015 Aug 1;44(4):1172–80.
- 18. Warmink-Perdijk WDB, Peters LL, Tigchelaar EF, Dekens JAM, Jankipersadsing
- SA, Zhernakova A, et al. Lifelines NEXT: a prospective birth cohort adding the
- 757 next generation to the three-generation Lifelines cohort study. Eur J Epidemiol.
- 758 2020 Feb;35(2):157–68.
- 19. Warmerdam R, Lanting P, Lifelines Cohort Study, Deelen P, Franke L. Idéfix:
- identifying accidental sample mix-ups in biobanks using polygenic scores.
- 761 Bioinformatics. 2022 Feb 15;38(4):1059–66.

- 762 20. Shah TS, Liu JZ, Floyd JAB, Morris JA, Wirth N, Barrett JC, et al. optiCall: a
- robust genotype-calling algorithm for rare, low-frequency and common variants.
- 764 Bioinformatics. 2012 Jun 15;28(12):1598–603.
- 765 21. Franke L, el Bannoudi H, Jansen DTSL, Kok K, Trynka G, Diogo D, et al.
- Association analysis of copy numbers of FC-gamma receptor genes for
- rheumatoid arthritis and other immune-mediated phenotypes. European Journal
- 768 of Human Genetics. 2016 Feb;24(2):263–70.
- 769 22. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al.
- Scikit-learn: Machine Learning in Python. Journal of Machine Learning Research.
- 771 2011;12(85):2825–30.
- 23. Loh PR, Danecek P, Palamara PF, Fuchsberger C, A Reshef Y, K Finucane H, et
- al. Reference-based phasing using the Haplotype Reference Consortium panel.
- 774 Nat Genet. 2016 Nov;48(11):1443–8.
- 24. statgen/Minimac4 [Internet]. Center for Statistical Genetics; 2024 [cited 2024 Aug
- 27]. Available from: https://github.com/statgen/Minimac4
- 25. Byrska-Bishop M, Evani US, Zhao X, Basile AO, Abel HJ, Regier AA, et al. High-
- coverage whole-genome sequencing of the expanded 1000 Genomes Project
- cohort including 602 trios. Cell. 2022 Sep 1;185(18):3426-3440.e19.
- 780 26. Pratt VM, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Scott SA, et al.
- 781 Recommendations for Clinical CYP2C19 Genotyping Allele Selection. The
- Journal of Molecular Diagnostics. 2018 May;20(3):269–76.

- 783 27. Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Kalman LV, et al.
- 784 Recommendations for Clinical Warfarin Genotyping Allele Selection. The Journal
- 785 of Molecular Diagnostics. 2020 Jul;22(7):847–59.
- 786 28. Pratt VM, Cavallari LH, Del Tredici AL, Gaedigk A, Hachad H, Ji Y, et al.
- 787 Recommendations for Clinical CYP2D6 Genotyping Allele Selection. The Journal
- 788 of Molecular Diagnostics. 2021 Sep;23(9):1047–64.
- 29. Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, et al. CYP3A4
- and CYP3A5 Genotyping Recommendations. The Journal of Molecular
- 791 Diagnostics. 2023 Sep 1;25(9):619–29.
- 30. Hofmeister RJ, Ribeiro DM, Rubinacci S, Delaneau O. Accurate rare variant
- phasing of whole-genome and whole-exome sequencing data in the UK Biobank.
- 794 Nat Genet. 2023 Jul;55(7):1243–9.
- 31. Kennedy S. Fluent in 3 Months. 2023 [cited 2024 Aug 28]. CEFR Levels: What
- They Are and How to Test Yourself. Available from:
- 797 https://www.fluentin3months.com/cefr-levels/
- 32. Krist AH, Tong ST, Aycock RA, Longo DR. Engaging patients in decision-making

and behavior change to promote prevention. Stud Health Technol Inform.

- 800 2017;240:284–302.
- 33. Merker VL, Hyde JK, Herbst A, Solch AK, Mohr DC, Gaj L, et al. Evaluating the
- 802 Impacts of Patient Engagement on Health Services Research Teams: Lessons
- from the Veteran Consulting Network. J Gen Intern Med. 2022 Apr;37(Suppl
- 804 1):33–41.

- 34. Ministerie van Volksgezondheid, Welzijn en Sport. Stand van zaken inzet DNA-
- technologie voor zorg en preventie [Internet]. Ministerie van Algemene Zaken;
- 807 2023 [cited 2024 Aug 27]. Available from:
- 808 https://www.rijksoverheid.nl/documenten/kamerstukken/2023/10/25/kamerbrief-
- 809 over-stand-van-zaken-inzet-dna-technologie-voor-zorg-en-preventie
- 35. Allison M, Patterson J, Burton S, Patel D, Brassil KJ. Digital engagement
- 811 preferences of individuals aged 65 and older with cancer. JCO. 2020 Oct
- 812 10;38(29_suppl):289–289.
- 813 36. Borghouts J, Eikey E, Mark G, De Leon C, Schueller SM, Schneider M, et al.
- 814 Barriers to and Facilitators of User Engagement With Digital Mental Health
- 815 Interventions: Systematic Review. J Med Internet Res. 2021 Mar
- 816 24;23(3):e24387.
- 817

818 Acknowledgements

819 The authors thank the UMCG Genomics Coordination Center, the UG Center for 820 Information Technology and their sponsors BBMRI-NL & TarGet for storage and 821 compute infrastructure. They thank Maaike van der Lee and Jesse Swen from the 822 department of Clinical Pharmacy and Toxicology of the Leiden University Medical 823 Center for providing the validation samples with known genotypes. The authors 824 thank Certe Groningen for their assistance in genotyping the CYP2D6 gene in a 825 number of cases and the GIC of the KNMP for providing their drug information texts 826 to generate layperson-friendly information. They also thank past and present 827 members of the ELSI-team of the UMCG for valuable feedback on the developed 828 communication materials.

829

830 Lifelines Cohort Study

- The Lifelines Biobank initiative has been made possible by funding from the Dutch
- 832 Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the
- 833 University Medical Center Groningen (UMCG the Netherlands), University of
- 834 Groningen and the Northern Provinces of the Netherlands. The generation and
- 835 management of GWAS genotype data for the Lifelines Cohort Study is supported by
- the UMCG Genetics Lifelines Initiative (UGLI). The authors wish to acknowledge the
- 837 services of the Lifelines Cohort Study, the contributing research centers delivering
- 838 data to Lifelines, and all the study participants.

839

- 840 Raul Aguirre-Gamboa (1), Patrick Deelen (1), Lude Franke (1), Jan A Kuivenhoven
- 841 (2), Esteban A Lopera Maya (1), Ilja M Nolte (3), Serena Sanna (1), Harold Snieder

842 (3), Morris A Swertz (1), Judith M Vonk (3), Cisca Wijmenga (1)

843

844 (1) Department of Genetics, University of Groningen, University Medical Center

845 Groningen, The Netherlands

846

- 847 (2) Department of Pediatrics, University of Groningen, University Medical Center
- 848 Groningen, The Netherlands

849

850 (3) Department of Epidemiology, University of Groningen, University Medical Center

851 Groningen, The Netherlands

853 Funding

- 854 This work was supported by SNN (Samenwerkingsverband Noord Nederland)
- 855 [OPSNN0229 PCH Ecosysteem WP4.4]; by Lifelines NEXT, which has been made
- possible by funds from a grant from the UMCG Hereditary Metabolic Diseases Fund;
- by the grants awarded to A.Z. (Netherlands Organization for Scientific Research
- 858 [NWO] VIDI Grant [016.178.056], a European Research Council [ERC] starting grant
- 859 [ERC-715772], and Gravitation program EXPOSOME-NL (NWO grant number
- 860 024.004.017)), and the Lifelines Biobank initiative, which has been made possible by
- 861 funds from FES (Fonds Economische Structuurversterking), SNN and REP
- 862 (Ruimtelijk Economisch Programma).
- 863 L.F. is supported by grants from NWO [ZonMW-VIDI 917.14.374, ZonMW-VICI
- 864 09150182010019], by an ERC Starting grant [637640 ImmRisk] and through a
- 865 Senior Investigator grant from the Oncode Institute. P.D. is funded by The
- 866 Netherlands Organisation for Health Research and Development (ZonMw) [VENI
- 867 09150161910057].

868

869 Author contributions

- 870 PL, BW, MS, NK, JD and LF: conceptualization,
- 871 PL, RW, HB, TO, JS, MB, ELM, TOM, PD, JD and LF: methodology,
- 872 RW, HB, BC, JS, LJ and LF: software,
- 873 PL, RW, HB, TO, JS and MB: validation,
- 874 PL, RW, HB, TO, JS, MB, ELM and SJ: formal analysis,
- 875 SJ, JGA and DTe: investigation,
- 876 LLN, LLCS, PD, NK, JD and LF: resources,
- 877 PL, RW, HB, JS, ELM, SJ, BC and LJ: data curation,

- 878 PL, RW, HB, TO and JS: manuscript original draft,
- 879 RW and JS: visualization,
- 880 BW, DTo, PD, NK, JD and LF: supervision,
- 881 PL, JS and JD: project administration,
- 882 NK, JD and LF: funding acquisition.
- 883

884 Data availability

885 Due to privacy reasons the individual-level data cannot be made publicly available

but can be made available upon reasonable request. The individual-level data from

- 887 Lifelines that support the findings in this publication were obtained from the Lifelines
- biobank under project application number ov21_0355. This request should be

directed to the Lifelines Research Office through email (<u>research@lifelines.nl</u>) or by

- 890 using the application form on their website (<u>https://www.lifelines.nl/researcher/how-</u>
- 891 to-apply/apply-here). Access to the Lifelines NEXT Project data will be granted to all
- qualified researchers and will be governed by the provisions laid out in the LLNEXT
- 893 Data Access Agreement: <u>https://groningenmicrobiome.org/?page_id=2598</u>. This

894 access procedure is in place to ensure that the data is requested solely for research

and scientific purposes, in compliance with the informed consent signed by Lifelines

- 896 NEXT participants. Scripts and other software central to this manuscript is available
- 897 on GitHub (<u>https://github.com/molgenis/PGx-passport-pilot/</u> and
- 898 <u>https://github.com/molgenis/asterix</u>). Other analyses of genotype data and publicly
- available reference data is performed using standard bioinformatics practices, for
- 900 which the code is made available upon request.
- 901

902 Conflicts of interest

- NdBV and DTo are members of the Dutch Pharmacogenetics Working Group 903
- (DPWG). All other authors report no conflict of interest. 904